Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Gabriella M. D'Andrea
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-Negative HER2-Overexpressed Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Related publications
A Randomized, Controlled Phase II Trial of Neoadjuvant Ado-Trastuzumab Emtansine, Lapatinib, and Nab-Paclitaxel Versus Trastuzumab, Pertuzumab, and Paclitaxel in HER2-positive Breast Cancer (TEAL Study)
Breast Cancer Research
Cancer Research
Oncology
An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
Oncologist
Cancer Research
Medicine
Oncology
Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis
Clinical Breast Cancer
Cancer Research
Oncology
Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib
AboutOpen
Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells With Primary Trastuzumab Resistance
Anti-Cancer Agents in Medicinal Chemistry
Cancer Research
Molecular Medicine
Pharmacology
Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
Frontiers in Oncology
Cancer Research
Oncology
Phase I Study of Intermittent High Dose Lapatinib Alternating With Capecitabine for HER2-positive Breast Cancer Patients With Central Nervous System Metastases
Clinical Cancer Research
Cancer Research
Oncology
BioPATH: A Biomarker Study in Asian Patients With HER2+ Advanced Breast Cancer Treated With Lapatinib and Other Anti-Her2 Therapy
Cancer Research and Treatment
Cancer Research
Oncology
